Plain-English translation of NCT05319314 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a new type of cancer treatment that uses your own immune cells (called T cells) to fight colorectal cancer. Researchers have modified these cells in the laboratory to help them recognize and attack cancer cells more effectively. The study will evaluate whether this treatment is safe and how well it works in patients whose cancer has come back or stopped responding to standard chemotherapy.
Patients with advanced colorectal cancer that has progressed despite standard treatments have very few options left. This medication represents a new approach—using the body's own immune system—to help patients who might otherwise have no effective treatments available.
You likely qualify if…
You likely don't qualify if…
You will first receive chemotherapy (fludarabine and cyclophosphamide) for 3 days to prepare your body. Then, your T cells will be collected, modified in a laboratory, and returned to you as a single infusion through an IV. After treatment, you will have regular follow-up visits to monitor your safety and how well the treatment is working. You will be followed closely for up to 5 years after receiving the treatment, and then continue in a long-term follow-up program for 15 years total.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States